Extensive research is being done on CRISPR-Cas9 in correcting genetic mutations which cause genetic diseases such as Down syndrome, spina bifida, anencephaly, and Tuner and Klinefelter syndromes using targeted gene therapy, if these genetic mutations are identified early enough in the embryo stages, which we …

Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. The company went public on 2 Feb 2016. This initial public offering was noted as being the first such from a company which aims to use …

Gene therapy is a way to fix a genetic problem at its source. The polymers are either translated into proteins, interfere with target gene expression, or possibly correct genetic mutations. The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene.

Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and β-Thalassemia. The mission of CRISPRTherapeutics is to develop transformative gene-based medicines for patients with serious diseases. Our therapeutic approach is to …

May 6, 2015 – CRISPR, a new genome editing tool, could transform the field of biology—and a recent study on genetically-engineered human embryos has converted this promise into media hype. But scientists have been tinkering with genomes for decades. Why is CRISPR suddenly such a big deal?

Mar 7, 2016 – CRISPR epigenetics. When geneticist Marianne Rots began her career, she wanted to unearth new medical cures. She studied gene therapy, which targets genes mutated in disease. But after a few years, she decided to change tack. “I reasoned that many more diseases are due to disturbed …

May 1, 2017 – In 2012, two men women, Jennifer Doudna and Emmanuelle Charpentier, discovered thatCRISPR could be used as a quick way to edit DNA when studying a Streptococcus pyogenes bacterium. (a.k.a., the bacterium that causes strep throat. Who knew those bacteria would actually be useful one day?)

June 8, 2016, CRISPR Therapeutics and Anagenesis biotechnologies announced strategic in-licensing and collaboration agreement to develop CRISPR/Cas9-based cell Therapies for Muscle Diseases; June 24, 2016, CRISPR Therapeutics raises additional $38M as Part of Series B financing. October 5, 2016,CRISPR …

May 10, 2015 – In an opinion piece published in the journal Science in March, a group of US scientists led by the Crispr co-developer Jennifer Doudna from the University of California, Berkeley recommended steps be taken to “strongly discourage” any attempts at germ-line modification therapythat would produce …